Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Last Updated on: 24 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Lincoln Pharmaceuticals Ltd

About the Company - Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 20/01/1995 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1995PLC024288 and registration number is 024288. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 472.08 Cr. and Equity Capital is Rs. 20.03 Cr. for the Year ended 31/03/2022.
PharmaceuticalsLincoln House, Ahmedabad Gujarat
NamePosition Held
Mr. Kishor M ShahChairman
Mr. Mahendra G PatelManaging Director
Mr. Hashmukh I PatelWhole Time Director
Mr. Munjal M PatelWhole Time Director
Mr. Ashish R PatelWhole Time Director
Mr. Rajnikant G PatelNon Executive Director
Mr. Meha M PatelIndependent Director
Mr. Saurin J ParikhIndependent Director
Mr. Pirabhai R SutharIndependent Director

Lincoln Pharmaceuticals Ltd. Share Price Update

Share PriceValue
Previous Day₹679.90

Basic Stock Data of Lincoln Pharmaceuticals Ltd

Market Cap 1,477 Cr.
Current Price 737
High / Low745/319
Stock P/E16.9
Book Value 273
Dividend Yield0.20 %
ROCE21.7 %
ROE15.5 %
Face Value 10.0

Data Source:

Competitors of Lincoln Pharmaceuticals Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
J B Chemicals & Pharmaceuticals Ltd 25,542 Cr. 1,6461,940/87549.7 1750.54 %22.4 %17.6 % 1.00
Nectar Lifescience Ltd 907 Cr. 40.445.7/14.4112 47.60.00 %0.18 %6.01 % 1.00
Solara Active Pharma Sciences Ltd 1,758 Cr. 488507/286 4070.00 %1.80 %1.44 % 10.0
Sanofi India Ltd 20,990 Cr. 9,1149,320/5,33036.5 3142.12 %41.4 %30.0 % 10.0
Krebs Biochemicals & Industries Ltd 158 Cr. 73.494.0/50.6 50.30.00 %28.6 %% 10.0
Industry Average222.2 Cr122.3639.64198.780.53%18.88%11.01%6.4

Lincoln Pharmaceuticals Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Operating Profit30201525292317172927172131
OPM %24%17%19%21%23%20%17%14%21%20%15%15%20%
Other Income1132332666489
Profit before tax29181525312417213231172537
Tax %27%27%18%29%25%25%34%28%26%29%26%25%25%
Net Profit21131318231811152422131928
EPS in Rs10.466.746.298.8511.528.795.507.4911.8410.796.279.4913.80

Lincoln Pharmaceuticals Ltd Quarterly Chart

Lincoln Pharmaceuticals Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Operating Profit14162026414753686687969095
OPM %7%8%10%10%10%13%15%18%17%21%20%18%18%
Other Income36277255115102227
Profit before tax711122033374662678496100110
Tax %30%16%16%24%28%25%25%22%23%26%28%27%
Net Profit5101015242835495162697381
EPS in Rs3.145.926.539.2014.5214.0617.3124.3625.7231.1234.6336.4040.35
Dividend Payout %19%10%9%11%7%9%9%6%6%5%4%4%

Lincoln Pharmaceuticals Ltd Profit & Loss Yearly Chart

Lincoln Pharmaceuticals Ltd Growth

Compounded Sales Growth
10 Years:10%
5 Years:7%
3 Years:10%
Compounded Profit Growth
10 Years:24%
5 Years:16%
3 Years:12%
Stock Price CAGR
10 Years:33%
5 Years:32%
3 Years:46%
1 Year:97%
Return on Equity
10 Years:17%
5 Years:17%
3 Years:17%
Last Year:16%

Lincoln Pharmaceuticals Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital16161616162020202020202020
Other Liabilities667293706448626371859983116
Total Liabilities212237260258275305347366389452534587663
Fixed Assets3865656698103117121123111132151147
Other Assets161169192190174186219225232259290339375
Total Assets212237260258275305347366389452534587663

Lincoln Pharmaceuticals Ltd Reserves and Borrowings Chart

Lincoln Pharmaceuticals Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 12-165254525275375697639
Cash from Investing Activity -27-1617-42-25-12-18-31-64-78-37
Cash from Financing Activity 1629-11-32-30-11-36-38-6-3-4
Net Cash Flow1-3-4-1-0-03-17-1-4-2

Lincoln Pharmaceuticals Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days127140154163739211112296989098
Inventory Days64546244366386759586121106
Days Payable125133174924054829210210512077
Cash Conversion Cycle66624311670100115106887891126
Working Capital Days90849714579115138143130119115123
ROCE %10%11%11%15%22%19%19%23%22%25%24%22%

Lincoln Pharmaceuticals Ltd Financial Efficiency Indicators Chart

Lincoln Pharmaceuticals Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
No. of Shareholders19,97721,41526,42030,27431,91332,44731,90231,73129,84629,08827,48028,670

Lincoln Pharmaceuticals Ltd Shareholding Pattern Chart

No. of Lincoln Pharmaceuticals Ltd Shareholders

Lincoln Pharmaceuticals Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
Motilal Oswal S&P BSE Healthcare ETF1060.080.01

Lincoln Pharmaceuticals Ltd ROCE Trend

Lincoln Pharmaceuticals Ltd EPS Trend

Lincoln Pharmaceuticals Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
Basic EPS (Rs.)36.4034.6331.1125.7224.36
Diluted EPS (Rs.)36.4034.6331.1125.7224.36
Cash EPS (Rs.)40.9738.6634.9129.4027.71
Book Value[Excl.RevalReserv]/Share (Rs.)250.86216.12187.85156.74134.85
Book Value[Incl.RevalReserv]/Share (Rs.)250.86216.12187.85156.74134.85
Revenue From Operations / Share (Rs.)254.78235.71212.09193.25183.09
PBDIT / Share (Rs.)55.7652.6646.4238.2936.44
PBIT / Share (Rs.)51.1848.6242.6434.6333.09
PBT / Share (Rs.)50.1647.9041.8633.6231.10
Net Profit / Share (Rs.)36.4034.6331.1225.7324.37
NP After MI And SOA / Share (Rs.)36.4034.6331.1125.7224.36
PBDIT Margin (%)21.8822.3421.8819.8119.90
PBIT Margin (%)20.0820.6220.1017.9118.07
PBT Margin (%)19.6820.3219.7317.3916.98
Net Profit Margin (%)14.2814.6914.6713.3113.31
NP After MI And SOA Margin (%)14.2814.6914.6613.3013.30
Return on Networth / Equity (%)14.5016.0216.5816.4218.08
Return on Capital Employeed (%)19.8921.9422.1021.3823.58
Return On Assets (%)12.4112.9713.5413.2113.33
Long Term Debt / Equity (X)
Total Debt / Equity (X)
Asset Turnover Ratio (%)0.900.950.991.031.02
Current Ratio (X)5.083.904.173.782.61
Quick Ratio (X)
Inventory Turnover Ratio (X)2.482.662.182.762.16
Dividend Payout Ratio (NP) (%)4.124.320.0011.666.15
Dividend Payout Ratio (CP) (%)3.663.870.0010.215.41
Earning Retention Ratio (%)95.8895.680.0088.3493.85
Cash Earning Retention Ratio (%)96.3496.130.0089.7994.59
Interest Coverage Ratio (X)55.0172.6859.4437.9518.23
Interest Coverage Ratio (Post Tax) (X)36.9148.7940.8626.5113.19
Enterprise Value (Cr.)646.08574.49436.11258.08449.66
EV / Net Operating Revenue (X)
EV / EBITDA (X)5.795.454.703.376.17
MarketCap / Net Operating Revenue (X)1.331.321.060.691.16
Retention Ratios (%)95.8795.670.0088.3393.84
Price / BV (X)1.351.441.200.851.58
Price / Net Operating Revenue (X)1.331.321.060.691.16

Lincoln Pharmaceuticals Ltd Profitability Ratios (%)

Lincoln Pharmaceuticals Ltd Liquidity Ratios

Lincoln Pharmaceuticals Ltd Liquidity Ratios (%)

Lincoln Pharmaceuticals Ltd Interest Coverage Ratios (%)

Lincoln Pharmaceuticals Ltd Valuation Ratios

Fair Value of Lincoln Pharmaceuticals Ltd Stock

Fair Value: ₹716.55

The stock is overvalued by 2.77% compared to the current price ₹737

*Investments are subject to market risks

Strength and Weakness of Lincoln Pharmaceuticals Ltd Stock

  1. The stock has a high average ROCE of 18.58%, which is a positive sign.
  2. The company has higher reserves (239.69 cr) compared to borrowings (41.00 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (359.69 cr) and profit (52.69 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 42.03 and average Dividend Yield of 19.36%.
  2. The stock has a high average Working Capital Days of 114.83, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 88.42, which may not be favorable.

About the Author

Author Avatar

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Lincoln Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE